Mylan announced the U.S FDA's final approval of its Abbreviated New Drug Application (ANDA) for repaglinide tablets (0.5, 1, and 2 mg), the generic version of Novo Nordisk's (Denmark) Prandin, indicated for glycemic control in adults with type 2 diabetes adjunct to diet and exercise. Furthermore, Mylan has now launched the generic product in the United States.